PA-BENTLEY-SYSTEMS
Bentley Systems, Incorporated, a leading global provider of comprehensive software solutions for advancing infrastructure , today announced the acquisition of Plaxis , the leading provider of geotechnical software, based in Delft, Netherlands, and the agreement to acquire soil engineering software provider SoilVision , based in Saskatchewan, Canada. The acquisitions, with Bentley’s market-leading borehole reporting and data management software gINT, serve to make Bentley a complete source for geotechnical professionals “going digital.” Finally, BIM advancements can be extended to the essential subsurface engineering of every infrastructure project.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180425006935/en/
Projects necessarily begin with geotechnical surveys and sampling, captured with gINT for versatile documentation and reporting. Next, professionals perform engineering related to soil properties, soil behavior, and groundwater flow using SoilVision’s SVOFFICE applications, supplemented by Plaxis’ offerings. Then soil-structure interaction is analyzed through Plaxis ’ design, simulation, and engineering software (e.g. PLAXIS 2D, PLAXIS 3D).
The new opportunity, by way of digital workflows enabled through Bentley’s comprehensive modeling environment, is for geotechnical applications to be integrated with Bentley’s structural applications (such as STAAD, RAM, and SACS) for unprecedented geo-structural engineering performance. As changes may occur in owner requirements, structural strategies, or site conditions (continuously surveyed through UAVs and Bentley’s ContextCapture for reality modeling), geotechnical analysis could be continuously applied for improved outcomes, as managed through ProjectWise collaboration services.
For today’s infrastructure demands, geotechnical considerations are coming to the fore. Urbanization, for instance, drives growth both vertically and underground, with emphasis on the capacity of foundations and tunnels. And new infrastructure projects of every type depend upon constructed dams, embankments, dikes, levees, and reservoirs to improve their resilience. Moreover, new asset types such as offshore wind turbine structures require new geotechnical analysis capabilities, in this case to be accomplished with Plaxis’ forthcoming MoDeTo software.
Because infrastructure assets are crucially linked to subsurface environs, they are vulnerable to geo-environmental risks including seismic activity, subsidence, and weather impacts. Leveraging new digital workflows which incorporate real-time monitoring and analytics during infrastructure operations, geotechnical professionals can play the increasingly valuable role they deserve in achieving geo-environmental resilience.
Bentley Systems CEO, Greg Bentley said, “My colleagues and I welcome our new teams from Plaxis and SoilVision, which have in common a zeal for applying science for better engineering practice. Dr. Ronald Brinkgreve from Plaxis and Dr. Murray Fredlund, founder of SoilVision , exemplify this. I believe that every geotechnical engineer has benefitted from Plaxis’ continuous advancement, in scope and quality, of tools for their discipline to add value. With a professional and dedicated management team led by Jan-Willem Koutstaal, Plaxis has become one of the most successful software businesses I have ever seen.”
Bentley added, “While most infrastructure engineering disciplines converged around intuitive 3D models, geotechnical applications seem to have followed a less graphically intensive development path, and so have remained isolated from cross-discipline workflows. This ‘disconnected’ mindset prevailed even while Plaxis , SoilVision , and gINT mainstreamed 3D innovations. Our BIM platform’s comprehensive modeling environment will finally embrace the geotechnical profession in digital workflows for every infrastructure project and asset.”
Tony O’Brien, global practice leader for geotechnics for Mott MacDonald, said, “PLAXIS is one of our core analysis tools being used across our global geotechnics practice. When used by experienced specialists, PLAXIS can analyze many of our most complex ground-structure interaction problems. In Bentley’s hands, we have high expectations that we can accomplish more through digital workflows made possible through integration of PLAXIS technology with Bentley’s comprehensive modeling environment—workflows that are compatible with Mott MacDonald’s commitment to connected thinking and solving complex infrastructure challenges.”
About Plaxis
Plaxis is a global market leader in geotechnical engineering software based on the finite element method, offering its applications to users in more than 100 countries worldwide. With a well-established reputation as the industry standard for geotechnical design, Plaxis software serves project owners, contractors, and consultants in civil engineering, oil and gas, offshore industries, and governmental organizations. www.plaxis.com
About SoilVision
Founded in 1997, SoilVision has championed 3D conceptual design and analysis of slope stability, groundwater flow, stress/deformation, contaminant transport, thermal flows in saturated/unsaturated soils, and coupled processes for geotechnical engineers and hydrogeologists. The software solves complex problems by performing numerical modeling and analysis of earth structures in the areas of soil and rock slope stability of earth dams, open pits, levees, embankments, and retaining walls. The software has been utilized for basic designs as well as advanced unsaturated analysis. The software is utilized extensively in the mining industry for the design and evaluation of large engineered earth structures. www.soilvision.com
About Bentley Systems
Bentley Systems is a global leader in providing engineers, architects, geospatial professionals, constructors, and owner-operators with comprehensive software solutions for advancing the design, construction, and operations of infrastructure. Bentley users leverage information mobility across disciplines and throughout the infrastructure lifecycle to deliver better-performing projects and assets. Bentley solutions encompass MicroStation applications for information modeling , ProjectWise collaboration services to deliver integrated projects , and AssetWise operations services to achieve intelligent infrastructure – complemented by comprehensive managed services offered through customized Success Plans.
Founded in 1984, Bentley has more than 3,500 colleagues in over 50 countries, more than $700 million in annual revenues, and since 2012 has invested more than $1 billion in research, development, and acquisitions. www.bentley.com
Related Images:
PLAXIS
3D
Caption:
PLAXIS 3D performs three-dimensional
analysis of deformation, soil-structure interaction, and stability in
geotechnical engineering and rock mechanics.
SoilVision
Caption:
SoilVision applications provide capabilities for engineering related to
soil properties, soil behavior, and groundwater flow.
##
Bentley, the “B” Bentley logo, AssetWise, ContextCapture, gINT, MicroStation, ProjectWise, RAM, SACS, and STAAD are either registered or unregistered trademarks or service marks of Bentley Systems, Incorporated or one of its direct or indirect wholly owned subsidiaries. All other brands and product names are trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180425006935/en/
Contact:
Bentley Systems
Press:
Jennifer Maguire, +1 610 458 2695
jennifer.maguire@bentley.com
Follow
us on Twitter:
@BentleySystems
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom